---
title: "CNTX: CTIM-76 achieved a 29% response rate and low-grade CRS in late-line ovarian cancer patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289805735.md"
description: "Interim phase I data for CTIM-76 in platinum-resistant ovarian cancer show a 29% response rate and favorable safety, with low-grade CRS and promising durability in heavily pretreated patients. Q3-week dosing is expected to further optimize efficacy and tolerability.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-15T15:24:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289805735.md)
  - [en](https://longbridge.com/en/news/289805735.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289805735.md)
generator: "portal-rs"
---

# CNTX: CTIM-76 achieved a 29% response rate and low-grade CRS in late-line ovarian cancer patients

Interim phase I data for CTIM-76 in platinum-resistant ovarian cancer show a 29% response rate and favorable safety, with low-grade CRS and promising durability in heavily pretreated patients. Q3-week dosing is expected to further optimize efficacy and tolerability.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CNTX.US](https://longbridge.com/en/quote/CNTX.US.md)

## Related News & Research

- [Context Therapeutics doses first patient in Phase 1 trial of CT-202 bispecific antibody](https://longbridge.com/en/news/298449932.md)
- [Parents loved sharing photos of their kids online. Then came AI.](https://longbridge.com/en/news/298753941.md)
- [HELP: Phase III data for HLP003 in adjunctive MDD expected Q4 2026; NDA filing targeted for 2028](https://longbridge.com/en/news/298938097.md)
- [HELP: Pivotal Phase III data for adjunctive MDD expected in Q4, with strong efficacy and safety signals](https://longbridge.com/en/news/299190021.md)
- [ZVRA: Broader patient reach, data-driven growth, and global expansion drive rare disease strategy](https://longbridge.com/en/news/299068474.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**